ARF6 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the ARF6 gene in the HAP1 human cell line. This loss-of-function model provides a genetically heterogeneous pool of edited cells, suitable for assays requiring consistent gene ablation across the population without clonal selection. The polyclonal format supports robust population-level studies of ARF6-dependent processes in membrane trafficking, cytoskeletal organization, and cell motility relevant to cancer biology.
The HAP1 host cell line is an adherent, fibroblast-like, near-haploid human line derived from KBM-7 chronic myeloid leukemia cells. Its haploid karyotype ensures that single-copy gene disruption yields a functional null phenotype, eliminating compensatory effects from a second allele. This feature makes HAP1 ideal for genetic loss-of-function screens and provides clear genotype-phenotype correlations in knockout studies.
ARF6 encodes a small GTPase of the ADP-ribosylation factor family, cycling between inactive GDP- and active GTP-bound states at the plasma membrane and endosomes. Activation by GEFs such as ARNO/CYTH2 and EFA6 promotes GTP loading, while GAPs like ACAPs and ASAP1 accelerate GTP hydrolysis. Active ARF6-GTP recruits effectors including PIP5K, generating PIP2 to drive actin polymerization, and activates PLD and Rac1 to remodel the cytoskeleton. ARF6 also orchestrates endocytic recycling of adhesion molecules, including E-cadherin, through interactions with JIP3/JIP4 and AMAP1. This signaling hub integrates inputs from receptor tyrosine kinases, integrins, and GPCRs to regulate cell migration and invasion.
Disruption of ARF6 in HAP1 cells profoundly perturbs endocytic trafficking and actin dynamics, impairing receptor recycling, cell adhesion, and migration. The leukemic origin of HAP1 makes this model especially relevant for investigating ARF6??s contribution to hematopoietic cell invasion and metastasis. Combined with the haploid background, ARF6 knockout HAP1 cells enable high-confidence dissection of ARF6-mediated processes without interference from wild-type alleles.
These polyclonal knockout cells are applicable in functional genomics screens, drug target validation for anti-metastatic agents, and genetic complementation studies. Key experimental assays include wound healing and Transwell migration/invasion to assess motility, immunofluorescence microscopy for actin and effector localization, endocytosis assays (transferrin uptake) to quantify recycling, and co-immunoprecipitation to map protein interactions. Additional uses encompass FRET-based GTPase activity measurements and FACS analysis of surface receptor expression. For technical support and ordering, contact Ascent Research.
